Oxford MEStar, the Oxford University bioengineering spinout company, today announced that it has been awarded funding to take part in a 36-month, € 6.84 Million project under the EU Interreg 2 Seas initiative. More information about the project can be found here: https://www.interreg2seas.eu/nl/3dmed

3DMed aims to improve affordability and large-scale accessibility of medical treatment using 3D printed devices. 15 Partners, including top universities and innovative companies in the Netherlands, Belgium, France and the UK will join forces in an unprecedented exercise to explore the full potential of the 3D printing technology for advanced medical care.

About Oxford MEStar

Oxford MEStar’s is a spin-out of the Institute of Biomedical Engineering at the University of Oxford and is developing manufacturing technologies for the regenerative medicine and cell therapy industries, including 3D printing and automated bioreactors. Oxford MEStar is aiming to become a leading technology partner for therapeutics developers and CDMOs. For more information please visit www.oxford-mestar.com